Skip to search formSkip to main contentSkip to account menu

response to lapatinib

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies… 
2011
2011
Durable Response to Lapatinib Plus Capecitabine in Trastuzumab-Resistant HER2 Over-expressing Metastatic Breast Cancer
HER2-directed therapy has become an important agent in the treatment of metastatic breast cancer, and has altered the natural… 
2009
2009
EGFR Gene Copy Number and Response to Lapatinib/Capecitabine in HER2 Positive Metastatic Breast Cancer Patients Pretreated with Trastuzumab.
Background: Lapatinib (L) is a potent and selective dual inhibitor of EGFR and HER2. In HER2 positive metastatic breast cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)